HC Wainwright Comments on LifeMD's Q3 Earnings (NASDAQ:LFMD)

Key Points

• HC Wainwright cut its Q3 2026 EPS estimate for LifeMD to a loss of $0.15 per share from a prior loss estimate of $0.05, while maintaining a Buy rating and $9.00 price target.
• LifeMD’s latest quarter fell short of expectations, reporting a $0.16 per-share loss versus the $0.15 consensus estimate and revenue of $47.28 million versus $49.16 million expected.
• Analyst sentiment remains mixed but leans positive: eight analysts rate the stock Buy and two rate it Sell, producing a Moderate Buy consensus and an average target price of $7.57.

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Research analysts at HC Wainwright reduced their Q3 2026 EPS estimates for LifeMD in a report issued on Friday, August 7th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.15) per share for the quarter, down from their prior estimate of ($0.05). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for LifeMD's current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for LifeMD's Q4 2026 earnings at $0.06 EPS, FY2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.12) EPS.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The company had revenue of $47.28 million for the quarter, compared to the consensus estimate of $49.16 million. LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%.

Several other equities research analysts also recently weighed in on the company. BTIG Research cut their price objective on LifeMD from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of LifeMD in a report on Tuesday, August 4th. UBS Group reiterated a "buy" rating on shares of LifeMD in a research report on Wednesday, May 27th. KeyCorp set a $5.00 price target on LifeMD and gave the company an "overweight" rating in a research note on Friday, August 7th. Finally, Wall Street Zen downgraded LifeMD from a "hold" rating to a "sell" rating in a research note on Saturday, July 18th. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $7.57.

LifeMD Price Performance

Shares of LifeMD stock opened at $3.45 on Monday. The company's 50 day moving average price is $4.26 and its two-hundred day moving average price is $3.97. The firm has a market capitalization of $166.29 million, a P/E ratio of -68.99 and a beta of 2.02. LifeMD has a fifty-two week low of $2.56 and a fifty-two week high of $7.32.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of LifeMD in the 4th quarter valued at about $36,000. R Squared Ltd bought a new position in shares of LifeMD during the first quarter worth about $41,000. Jain Global LLC bought a new position in shares of LifeMD during the fourth quarter worth about $45,000. Quarry LP acquired a new position in shares of LifeMD in the third quarter worth approximately $52,000. Finally, Tower Research Capital LLC TRC boosted its holdings in LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company's stock valued at $64,000 after acquiring an additional 2,452 shares during the last quarter. 35.52% of the stock is owned by institutional investors.

LifeMD Company Profile

LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source